NASDAQ:SABS SAB Biotherapeutics (SABS) Stock Price, News & Analysis → The last Republican president? (From The Freeport Society) (Ad) Free SABS Stock Alerts $3.23 -0.07 (-2.12%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$3.20▼$3.4450-Day Range$2.57▼$4.7252-Week Range$2.36▼$10.50Volume8,771 shsAverage Volume17,597 shsMarket Capitalization$29.81 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get SAB Biotherapeutics alerts: Email Address SAB Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside302.5% Upside$13.00 Price TargetShort InterestHealthy0.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.08) to ($3.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.16 out of 5 starsMedical Sector543rd out of 917 stocksBiological Products, Except Diagnostic Industry77th out of 153 stocks 3.4 Analyst's Opinion Consensus RatingSAB Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSAB Biotherapeutics has only been the subject of 3 research reports in the past 90 days.Read more about SAB Biotherapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.45% of the float of SAB Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSAB Biotherapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SAB Biotherapeutics has recently increased by 50.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSAB Biotherapeutics does not currently pay a dividend.Dividend GrowthSAB Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SABS. Previous Next 1.9 News and Social Media Coverage News SentimentSAB Biotherapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for SAB Biotherapeutics this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders26.46% of the stock of SAB Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.82% of the stock of SAB Biotherapeutics is held by institutions.Read more about SAB Biotherapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for SAB Biotherapeutics are expected to grow in the coming year, from ($4.08) to ($3.26) per share.Price to Book Value per Share RatioSAB Biotherapeutics has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about SAB Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About SAB Biotherapeutics Stock (NASDAQ:SABS)SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.Read More SABS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SABS Stock News HeadlinesJune 7, 2024 | americanbankingnews.comSAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated by Analysts at Brookline Capital ManagementMay 30, 2024 | globenewswire.comSAB Biotherapeutics Announces Departure of Chief Financial OfficerMay 25, 2024 | bizjournals.comPharma company moves headquarters from Midwest to Miami BeachMay 21, 2024 | finanznachrichten.deSAB Biotherapeutics, Inc.: FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB BiotherapeuticsMay 21, 2024 | markets.businessinsider.comSAB Biotherapeutics: Strong Buy Rating on Robust Financials and Promising Diabetes Drug DevelopmentMay 21, 2024 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company UpdatesMay 21, 2024 | markets.businessinsider.comSAB Biotherapeutics Gets FDA Clearance To Advance Phase 1 Trial Of SAB-142 In Type-1 DiabetesMay 21, 2024 | globenewswire.comFDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB BiotherapeuticsMay 20, 2024 | globenewswire.comSAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company UpdatesMay 6, 2024 | globenewswire.comSAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of DirectorsApril 17, 2024 | msn.comSAB Biotherapeutics (SABS) Price Target Decreased by 10.00% to 18.36April 16, 2024 | msn.comSAB Leaps on Completing Latest CohortApril 16, 2024 | globenewswire.comSAB Biotherapeutics Provides SAB-142 Trial UpdateApril 8, 2024 | globenewswire.comSAB Biotherapeutics to Present at INNODIA Annual MeetingApril 4, 2024 | markets.businessinsider.comSAB Biotherapeutics: Strong Financial Position and Promising SAB-142 Pipeline Merit Buy RatingApril 4, 2024 | globenewswire.comSAB Biotherapeutics to Present at the Needham Virtual Healthcare ConferenceApril 1, 2024 | finance.yahoo.comSAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsApril 1, 2024 | finance.yahoo.comSAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 29, 2024 | globenewswire.comSAB Biotherapeutics Reports Full Year 2023 Operating and Financial ResultsMarch 25, 2024 | markets.businessinsider.comSAB Collaborates With Naval Medical Research To Develop Potential Influenza Treatment; Stock DropsMarch 25, 2024 | globenewswire.comSAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza TreatmentFebruary 23, 2024 | globenewswire.comSAB Biotherapeutics to Present at the BIO CEO & Investor ConferenceFebruary 8, 2024 | finance.yahoo.comSAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 8, 2024 | finance.yahoo.comSAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 2, 2024 | marketwatch.comSAB Biotherapeutics Names Samuel Reich Chief ExecutiveSee More Headlines Receive SABS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/20/2024Today6/13/2024Next Earnings (Estimated)8/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:SABS CUSIPN/A CIK1833214 Webwww.bigcypressaccorp.com Phone605-679-6980FaxN/AEmployees57Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$25.00 Low Stock Price Target$6.00 Potential Upside/Downside+302.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,190,000.00 Net Margins-1,531.26% Pretax Margin-1,531.26% Return on Equity-109.90% Return on Assets-72.78% Debt Debt-to-Equity Ratio0.06 Current Ratio5.65 Quick Ratio5.65 Sales & Book Value Annual Sales$2.24 million Price / Sales13.31 Cash FlowN/A Price / Cash FlowN/A Book Value$6.21 per share Price / Book0.52Miscellaneous Outstanding Shares9,230,000Free Float6,787,000Market Cap$29.81 million OptionableNot Optionable Beta0.63 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Samuel J. Reich (Age 49)CEO & Executive Chairman Comp: $363.2kDr. Eddie Joe Sullivan Ph.D. (Age 57)Co-Founder, President & Director Comp: $402.56kMs. Christine E. Hamilton M.B.A. (Age 68)Co-Founder & Independent Director Comp: $25kMr. Michael George King Jr. (Age 63)EVP & CFO Comp: $60.58kDr. Christoph Bausch M.B.A. (Age 53)Ph.D., Executive VP & COO Comp: $443.2kDr. Alexandra Kropotova M.B.A. (Age 51)M.D., Executive VP & Chief Medical Officer Comp: $774.45kDr. Edward D. Hamilton D.V.M.Co-Founder & Board ObserverDr. Carlos N. Carillo Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsVerastemNASDAQ:VSTMCurisNASDAQ:CRISFortress BiotechNASDAQ:FBIOBolt BiotherapeuticsNASDAQ:BOLTMolecular TemplatesNASDAQ:MTEMView All CompetitorsInsiders & InstitutionsBVF Inc. ILSold 8,260,456 shares on 5/16/2024Ownership: 9.944%Eddie Joe SullivanBought 1,740 shares on 12/7/2023Total: $1,531.20 ($0.88/share)Michael KingBought 5,000 shares on 11/30/2023Total: $4,500.00 ($0.90/share)Samuel J ReichBought 11,000 shares on 11/29/2023Total: $9,790.00 ($0.89/share)View All Insider TransactionsView All Institutional Transactions SABS Stock Analysis - Frequently Asked Questions Should I buy or sell SAB Biotherapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SABS shares. View SABS analyst ratings or view top-rated stocks. What is SAB Biotherapeutics' stock price target for 2024? 4 brokerages have issued twelve-month price objectives for SAB Biotherapeutics' stock. Their SABS share price targets range from $6.00 to $25.00. On average, they anticipate the company's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 302.5% from the stock's current price. View analysts price targets for SABS or view top-rated stocks among Wall Street analysts. How have SABS shares performed in 2024? SAB Biotherapeutics' stock was trading at $0.6875 at the beginning of the year. Since then, SABS shares have increased by 369.8% and is now trading at $3.23. View the best growth stocks for 2024 here. Are investors shorting SAB Biotherapeutics? SAB Biotherapeutics saw a increase in short interest in May. As of May 31st, there was short interest totaling 33,900 shares, an increase of 50.7% from the May 15th total of 22,500 shares. Based on an average trading volume of 17,400 shares, the short-interest ratio is presently 1.9 days. Currently, 0.5% of the company's stock are short sold. View SAB Biotherapeutics' Short Interest. When is SAB Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 19th 2024. View our SABS earnings forecast. How were SAB Biotherapeutics' earnings last quarter? SAB Biotherapeutics, Inc. (NASDAQ:SABS) posted its earnings results on Monday, May, 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.98) by $0.44. The company earned $0.95 million during the quarter. SAB Biotherapeutics had a negative net margin of 1,531.26% and a negative trailing twelve-month return on equity of 109.90%. Who are SAB Biotherapeutics' major shareholders? SAB Biotherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BVF Inc. IL (9.94%). Insiders that own company stock include Christine E Hamilton, Eddie Joe Sullivan, Michael King and Samuel J Reich. View institutional ownership trends. How do I buy shares of SAB Biotherapeutics? Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SABS) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredMy 3 Top CryptocurrenciesMore than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.